LIGAND PHARMACEUTICALS INCORPORATED
NASDAQ: LGND
▼
72.11
-1.52
-2.06%
1 Day
-
Open
73.94
-
Previous Close
73.63
-
Volume (Avg)
14 (141.02k)
-
Day's Range
71.70-74.11
-
52Wk Range
45.25-83.95
-
Market Cap.
1.26B
-
Dividend Rate ( Yield)
-
-
Beta
-
-
Shares Outstanding
-
-
P/E Ratio (EPS)
71.86 (-)
Top Stories
-
AbbVie (ABBV) Gets FDA Rejection for Parkinson's Candidate
Zacks.com 6 days ago -
Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78%
Zacks.com -
Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA
Zacks.com -
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges
Zacks.com -
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
Zacks.com 3/21/2023 -
San Diego's Lenz Therapeutics snags $83.5M for once-a-day eye drops to replace near-vision glasses
San Diego Union Tribune -
Ligand Pharmaceuticals: Expanding Royalty Portfolio And Strong Drug Pipeline
Seeking Alpha -
Ligand Pharmaceuticals Stock (NASDAQ:LGND), Analyst Ratings, Price Targets, Predictions
Benzinga.com -
Ligand Pharmaceuticals, Inc. (LGND) Q4 2022 Earnings Call Transcript
Seeking Alpha -
Ligand Pharmaceuticals Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
Yahoo -
Ligand Pharmaceuticals Inc.
Wall Street Journal -
Ligand Pharmaceuticals Incorporated (LGND)
Yahoo Finance -
Ligand: Q4 Earnings Snapshot
The Middletown Press -
Ligand Pharmaceuticals Inc.
Barron's -
Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue Estimates
Yahoo 2/23/2023Ligand Pharmaceuticals (LGND) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.80 per share a year ago.
-
Ligand: Q4 Earnings Snapshot
Times Union -
Ligand Pharmaceuticals
PMLiVE -
Ligand: Q4 Earnings Snapshot
San Antonio Express-News
